A Phase 2b study of single agent tasquinimod
Latest Information Update: 06 Dec 2020
At a glance
- Drugs Tasquinimod (Primary)
- Indications Multiple myeloma; Solid tumours
- Focus Therapeutic Use
- 06 Dec 2020 New trial record
- 24 Nov 2020 According to an Active Biotech media release, the study expected to start in 2023.